Search

everythinglearnresearchcommunity

for

Search:↓

Oral spironolactone's effectiveness for adult female acne is not well-supported by strong evidence.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Spironolactone plus finasteride reduces hirsutism more effectively.

Prolactin may be important for skin growth and immune function.

Metformin and rosiglitazone both improved insulin use and hormonal symptoms in women with PCOS.

Hormonal treatments are effective as a second-line option for moderate-to-severe acne in females, but should be used with caution due to health risks.

Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.

High androgen levels can cause excessive hair growth and may indicate serious health issues, including heart disease and fertility problems.

Genetic mutations can affect female sexual development, requiring personalized medical care.

The document summarizes medical findings on topics like heart rhythm treatment, sleep apnea therapy, and various health conditions and treatments.

Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.

Menopause reduces skin collagen and elasticity, and while estrogen therapy can help, its risks require careful consideration.

Skin and hair changes in horses can indicate serious diseases, and recognizing these signs is important for treatment and management.

The most effective treatments for hair loss are minoxidil, finasteride, PRP, and hair transplants, with steroids and immunosuppressants for autoimmune types.

Androgens can cause acne, excess hair, and hair loss, treatable with dermatologist-guided therapies.

The May issue discussed publishing agreements and four studies on cholesterol in hair, cancer cell changes, hormones in the uterus, and skin protein effects.

Finasteride effectively reduces hair growth in women with polycystic ovary syndrome or idiopathic hirsutism.

The document concludes with guidance for doctors on diagnosing and treating hirsutism effectively and safely.

Hormonal therapy is a treatment option for acne, the only medical treatment for hirsutism, and the most promising for androgenetic alopecia.

Experts recommend using evidence-based methods to diagnose and treat hirsutism, focusing on symptoms and underlying causes.

Cushing's syndrome can cause serious health problems, and early treatment is crucial, but some issues may remain after treatment.

Insulin resistance is a key factor in polycystic ovary syndrome, but genetics may also contribute.

Hormones, especially androgens, play a big role in acne, but most acne sufferers don't have a hormone disorder. Hormonal treatments, including birth control pills, can be very effective for women whose acne doesn't improve with regular treatments.

Hormonal treatments, including birth control and antiandrogens, can effectively treat acne in women.

Gynecologists should provide comprehensive care for transgender patients, including mental health evaluation, hormone therapy, and surgical options, while monitoring for side effects and ensuring patient safety.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

Excessive hair growth in women often has no known cause and is not linked to race or other hormonal symptoms.

Prolactin may play a significant role in skin and hair health and could be a target for treating skin and hair disorders.

The document concludes that correct diagnosis and management of PCOS are important, and more research is needed on its risks and treatments.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.